Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands. more
Time Frame | ANL | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.54% | 1.76% | -2.37% |
1-Month Return | -13.54% | 0.33% | -3.79% |
3-Month Return | 1.02% | -8.58% | -0.46% |
6-Month Return | -43.29% | -4.26% | 3.58% |
1-Year Return | -78.12% | 1.27% | 22.47% |
3-Year Return | -86.8% | 5.33% | 25.17% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 45.73M | - | 5.00M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":10.93,"profit":true}] |
Cost of Revenue | 1.48M | 1.51M | - | 2.04M | 2.22M | [{"date":"2019-12-31","value":66.65,"profit":true},{"date":"2020-12-31","value":67.95,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":91.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (1.48M) | (1.51M) | 45.73M | (2.04M) | 2.78M | [{"date":"2019-12-31","value":-3.24,"profit":false},{"date":"2020-12-31","value":-3.3,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-4.46,"profit":false},{"date":"2023-12-31","value":6.07,"profit":true}] |
Gross Margin | - | - | 100.00% | (Infinity%) | 55.56% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":55.56,"profit":true}] |
Operating Expenses | 17.64M | 24.59M | 54.37M | 67.27M | 72.55M | [{"date":"2019-12-31","value":24.31,"profit":true},{"date":"2020-12-31","value":33.9,"profit":true},{"date":"2021-12-31","value":74.94,"profit":true},{"date":"2022-12-31","value":92.72,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (19.12M) | (26.10M) | (8.65M) | (67.27M) | (67.55M) | [{"date":"2019-12-31","value":-1911704000,"profit":false},{"date":"2020-12-31","value":-2610039000,"profit":false},{"date":"2021-12-31","value":-864600000,"profit":false},{"date":"2022-12-31","value":-6727000000,"profit":false},{"date":"2023-12-31","value":-6755100000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | (49.37M) | 8.05M | (37.41M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-613.51,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-464.84,"profit":false}] |
Pre-Tax Income | (17.83M) | (63.38M) | (56.68M) | (58.79M) | (104.23M) | [{"date":"2019-12-31","value":-1783004200,"profit":false},{"date":"2020-12-31","value":-6337831700,"profit":false},{"date":"2021-12-31","value":-5667800000,"profit":false},{"date":"2022-12-31","value":-5879000000,"profit":false},{"date":"2023-12-31","value":-10422800000,"profit":false}] |
Income Taxes | (1.00) | 3.00 | (46.19M) | 8.31M | 643.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-555.68,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.74,"profit":true}] |
Income After Taxes | - | - | (10.49M) | (67.10M) | (104.87M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1049000000,"profit":false},{"date":"2022-12-31","value":-6710200000,"profit":false},{"date":"2023-12-31","value":-10487100000,"profit":false}] |
Income From Continuous Operations | - | - | (56.68M) | (58.79M) | (104.87M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-5667800000,"profit":false},{"date":"2022-12-31","value":-5879000000,"profit":false},{"date":"2023-12-31","value":-10487100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (17.83M) | (63.38M) | (56.68M) | (58.79M) | (104.87M) | [{"date":"2019-12-31","value":-1783004200,"profit":false},{"date":"2020-12-31","value":-6337831700,"profit":false},{"date":"2021-12-31","value":-5667800000,"profit":false},{"date":"2022-12-31","value":-5879000000,"profit":false},{"date":"2023-12-31","value":-10487100000,"profit":false}] |
EPS (Diluted) | - | - | - | - | (2.18) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-218,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ANL | |
---|---|
Cash Ratio | 1.80 |
Current Ratio | 1.85 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ANL | |
---|---|
ROA (LTM) | -46.41% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ANL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.50 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.50 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ANL | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 14.61 |
P/B | 1.37 |
Price/FCF | NM |
EV/R | 2.92 |
EV/Ebitda | NM |
Adlai Nortye Ltd. American Depositary Shares (ANL) share price today is $2.04
Yes, Indians can buy shares of Adlai Nortye Ltd. American Depositary Shares (ANL) on Vested. To buy Adlai Nortye Ltd. American Depositary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Adlai Nortye Ltd. American Depositary Shares (ANL) via the Vested app. You can start investing in Adlai Nortye Ltd. American Depositary Shares (ANL) with a minimum investment of $1.
You can invest in shares of Adlai Nortye Ltd. American Depositary Shares (ANL) via Vested in three simple steps:
The 52-week high price of Adlai Nortye Ltd. American Depositary Shares (ANL) is $17.48. The 52-week low price of Adlai Nortye Ltd. American Depositary Shares (ANL) is $1.85.
The price-to-earnings (P/E) ratio of Adlai Nortye Ltd. American Depositary Shares (ANL) is
The price-to-book (P/B) ratio of Adlai Nortye Ltd. American Depositary Shares (ANL) is 1.37
The dividend yield of Adlai Nortye Ltd. American Depositary Shares (ANL) is 0.00%
The market capitalization of Adlai Nortye Ltd. American Depositary Shares (ANL) is $73.06M
The stock symbol (or ticker) of Adlai Nortye Ltd. American Depositary Shares is ANL